BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b158 (Published 05 February 2009)
Cite this as: BMJ 2009;338:b158
Correspondence to: A Burns alistair.burns@manchester.ac.uk
Rwanda Guidelines for variation to registered pharmaceutical products.
Saving Lives: Universal access to Trauma Services in Kenya
The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines ...faster over the three-year estimated life of an ITN; therefore, the added impact of
pyrethroid-PBO ITNs over that of pyrethroid-only LLINs may decline over time. The evidence comes from two sites in
eastern Africa with pyrethroid resistance and not from other geographies where transmission levels and vector characteristics
may vary. PBO acts by inhibiting certain metabolic enzymes, primarily oxidases, and so are likely to provide greater protection
than pyrethroid-only LLINs where mosquitoes display mono-oxygenase-based insecticide resistance mechanisms.
more
This is an abridged version of the 2019 Standards containing the evidence-based recommendations most pertinent to primary care. The tables and figures have been renum-bered from the original document to match this version. The complete 2019 Standards of Care do...cument, including all supporting references, is available at professional.diabetes.org/standards.
This is an abridged version of the American Diabetes Association’s Standards of Medical Care in Diabetes—2019. Diabetes Care2018;42(Suppl. 1):S1–S194. The complete 2019 Standards supplement, including all supporting references, is available at professional.diabetes.org/standards.
more
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Обеспечение возможностей быстрого развертывания сил и средств для оказания неотложной помощи и интенсивного лечения (6 апреля 2020 г.)
Главный вопрос, рассматривае...мый в предлагаемом техническом руководстве, заключается в том, как
обеспечить возможности быстрого развертывания сил и средств для оказания неотложной помощи и
интенсивного лечения больных COVID-19 при сохранении основных видов больничных услуг.
more
Joint United Nations Programme on HIV/AIDS (UNAIDS).
The coronavirus outbreak that began in 2019 (COVID-19) threatens to reverse years of hard-won gains in preventing and treating HIV. Fragile health systems are further stressed as health workers navigate an increased client load and demands at work while also being concerned for their own health and ...that of their families. Health facilities have been redesigned to care for patients with COVID-19, posing challenges to other services. Governments and civil society organizations have redirected scarce resources and shifted programming priorities to respond to the pandemic. Several countries have reported intermittent declines in HIV testing and diagnosis, antenatal care visits, collection of antiretroviral medicines (ARVs) by people living with HIV, and attendance at clinic appointments. Community-based education and support programmes have had to rapidly adapt to restrictions on movement and public gatherings. Children, adolescents, and women have experienced multiple deprivations due to the adverse impact of the pandemic.
more
Q10: In individuals with psychotic disorders (including schizophrenia) and bipolar disorders are psychoeducation, family interventions and cognitive-behavioural therapy feasible and effective?
Guidelines for the treatment of human African trypanosomiasis. Web Annex A. Commissioned by WHO Cochrane Response
WHO Guidelines for the Treatment of Human African Trypanosomiasis. Web Annex B
UN GUIDE POUR L’APPROVISIONNEMENTEN MÉDICAMENTS/ A guide for drug supply
Bochure in English and French